Mivebresib

CAT: 0804-HY-100015-09Size: 1 gDry Ice: NoHazardous: No

1 / 1

CAT#:0804-HY-100015-09Size:1 g

Selected

24/48H Stock Items & 2 to 6 Weeks non Stock Items.

Quick Request Actions

Description

Mivebresib (ABBV-075) is a potent and orally active bromodomain and extraterminal domain (BET) bromodomain inhibitor. Mivebresib binds to BRD4 with a Ki of 1.5 nM[1].

CAS Number

1445993-26-9

Product Name Alternative

ABBV-075

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Apoptosis; Epigenetic Reader Domain

Type

Reference compound

Related Pathways

Apoptosis; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Mivebresib.html

Purity

99.69

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CCS(=O)(NC1=CC=C(OC2=CC=C(F)C=C2F)C(C3=CN(C)C(C4=C3C=CN4)=O)=C1)=O

Molecular Formula

C22H19F2N3O4S

Molecular Weight

459.47

Precautions

H315, H319, H335

References & Citations

[1]EJ Faivre et al. Abstract 4694: ABBV-075, a novel BET family inhibitor, disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Phase 1

Chemical Information

Mivebresib

Mivebresib is a small molecule drug. The usage of the INN stem '-bresib' in the name indicates that Mivebresib is a inhibitor of the bromodomain and extra-terminal motif (BET) family of bromodomain (BRD) protein, antineoplastic. Mivebresib is under investigation in clinical trial NCT04480086 (Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis). Mivebresib has a monoisotopic molecular weight of 459.11 Da.

CAS Number	1445993-26-9
PubChem CID	71600087
IUPAC Name	N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide
Molecular Formula	C22H19F2N3O4S
Molecular Weight	459.5
XLogP	2.9
Topological Polar Surface Area	99.9
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	6
Heavy Atom Count	32
Formal Charge	0
Complexity	834

SMILES

CCS(=O)(=O)NC1=CC(=C(C=C1)OC2=C(C=C(C=C2)F)F)C3=CN(C(=O)C4=C3C=CN4)C

InChI

InChI=1S/C22H19F2N3O4S/c1-3-32(29,30)26-14-5-7-19(31-20-6-4-13(23)10-18(20)24)16(11-14)17-12-27(2)22(28)21-15(17)8-9-25-21/h4-12,25-26H,3H2,1-2H3

InChIKey

RDONXGFGWSSFMY-UHFFFAOYSA-N

Chemical Structure

2D Structure

CAS: 1445993-26-9

CID: 71600087

Formula: C22H19F2N3O4S

MW: 459.5

Interactive 3D Structure

Loading 3D structure...

View on PubChem Raw 3D data

Computed Properties

Property	Value
Molecular Weight	459.5
XLogP3	2.9
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	6
Exact Mass	459.10643359
Monoisotopic Mass	459.10643359
Topological Polar Surface Area	99.9 Å²
Heavy Atom Count	32
Formal Charge	0
Complexity	834
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently-Bonded Unit Count	1
Compound Is Canonicalized	Yes

Alternative Products

Catalog	Name
B1564-5	Mivebresib
MBS3842201-01	Mivebresib (ABBV-075)
A17226-50	Mivebresib (ABBV-075) 50mg

Mivebresib

Chemical Information

Alternative Products

Popular Products